// App-Quantinova.ai

757 : Phase II Study of the Frontline Hyper-CVAD in Combination with Ponatinib for Patients with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Koji Sasaki

Principal Investigators

  • Farhad Ravandi

  • Guillermo Garcia-Manero

  • Courtney D. DiNardo

  • Marina Konopleva

  • Zeev Estrov

  • Nitin Jain

  • William G. Wierda

  • Twilla Victoria Jeanis

  • Jorge E. Cortes

  • Susan M. -Brien

  • Hagop M. Kantarjian

  • Naval G. Daver

  • Naveen Pemmaraju

  • Deborah A Thomas

  • Rita B. Khouri

  • Musa Yilmaz

  • Tapan M. Kadia

  • Nicholas J. Short

  • Rebecca Garris

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The Scott Department of Urology, Baylor College of Medicine, Houston, TX

  • Chao Family Comprehensive Cancer Center, University of California, Orange, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Methotrexate

  • Vincristine

  • Cytarabine liposomal

  • Prednisone

  • Ponatinib

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved